Loading company…
Polskie Konsorcjum Szpiczakowe runs clinical and biological studies on multiple myeloma, such as the REBEL and ATLAS studies.
Established in 2014 and based in Poznan, Poland, the consortium plans, starts and runs prospective clinical and biological studies on multiple myeloma. Its main studies are REBEL, which tests new treatment approaches, and ATLAS, which looks at maintenance therapy for newly diagnosed patients after autologous transplant. Funding comes mainly from non-commercial research grants, such as those from the Polish Agency for Medical Research. Warsaw Equity acquired the consortium in June 2000, with financial terms not disclosed.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at Polskie Konsorcjum Szpiczakowe? This is my company